CLINICAL TRIALS Flashcards
(121 cards)
1
Q
It is systematic process that is intended to find out the safety and efficacy of a drug/device in treating/preventing/diagnosing a disease or a medical condition.
A
CLINICAL TRIAL
2
Q
A clinical trial is a systematic process that is intended to find out the safety and efficacy of a drug/device in ___/____/___ a disease or a medical condition.
A
TREATING/ PREVENTING/ DIAGNOSING
3
Q
It involves the study of the effect of an investigational drug/any other intervention in a defines population/participant.
A
CLINICAL TRIAL
4
Q
The new FDA guidelines include five (5) phases:
A
PHASE 0 (micro-dosing studies)
PHASE 1
PHASE 2
PHASE 3
PHASE 4
5
Q
Phase 0 and Phase 2 are called?
A
EXPLORATORY TRIAL PHASES
6
Q
Phase 1 is termed the?
A
NON-THERAPEUTIC PHASE
7
Q
Phase 3 is knows as the?
A
THERAPEUTIC CONFIRMATORY PHASE
8
Q
Phase 4 is called the?
A
POST-APPROVAL OR POST-MARKETING SURVEILLANCE PHASE
9
Q
Type of Clinical Trial:
A
RAMDOMIZED TRIAL
OPEN LABEL
BLINDED (SINGLE BLIND)
DOUBLE-BLINE (DOUBLE-BLIND)
PLACEBO
ADD-ON
SINGLE CENTER
MULTI-CENTER
10
Q
Study participants are randomly assigned to a group.
A
RANDOMIZED TRIAL
11
Q
Both study subjects and the researchers are aware of the drug being tested.
A
OPEN-LABEL
12
Q
In____ , the subject has no idea about the group (test/control) in which they are placed
A
BLINDED (SINGLE-BLIND)
13
Q
In the ____ study, the subjects as well ad the investigator have no idea about the test/control group.
A
DOUBLE-BLIND (DOUBLE-BLIND)
14
Q
A substance that appears like a drug but has no active moiety.
A
PLACEBO
15
Q
An additional drug apart from the clinical trial drug given to a group of study participants.
A
ADD ON
16
Q
A study being carried out a particular place/location/center.
A
SINGLE CENTER
17
Q
A study is being carried out at multiple places/location/centers.
A
MULTI-CENTER
18
Q
Clinical trials are broadly classified into?
A
CONTROLLED and UNCONTROLLED TRIALS
19
Q
Are potentially biased, and the results of such research are not considered as equally as the controlled studies.
A
UNCONTROLLED TRIALS
20
Q
Are considered the most effective clinical trials, wherein the bias is minimized, and the results are considered reliable.
A
RANDOMIZED CONTROLLED TRIALS (RCTs)
21
Q
The participants are assigned to a case or a control group baser on flipping coin results/computer assignment.
A
SIMPLE RANDOMIZATION
22
Q
Equal and small group of both cases and controls.
A
BLOCK RANDOMIZATION
23
Q
Randomization based on the age of the participant and other covariates.
A
STRATIFIED RANDOMIZATION
24
Q
Sequential assignment of a new participants into a group based on the covariates.
A
CO-VARIATE ADAPTIVE RANDOMIZATION/MINIMIZATION
25
One intervention is administered to one-half of the body and the comparator intervention is assigned to another half of the body.
RANDOMIZATION BY BODY HALVES Or PAIRED ORGANS (SPLIT BODY TRIALS)
26
Intervention is administered to clusters/groups by randomization to prevent contamination and either active or comparator intervention is administered for each group.
CLUSTERED RANDOMIZATION
27
Patients are allocated to one of the two trial arms.
ALLOCATION BY RANDOMIZED CONSENT (ZELEN TRIALS)
28
Clinical research design has two major types:
NON-INTERVENTIONAL/OBSERVATIONAL
INTERVENTIONAL/EXPERIMENTAL
29
It may have a comparator group (analytical studies like case-control and cohort studies), or without it (descriptive study)
NON-INTERVENTIONAL STUDIES
30
The non-interventional studies may have a _____ (analytical studies like case-control and cohort studies) or without it (descriptive studies)
COMPARATOR GROUP
31
The experimental studies may be either?
RANDOMIZED OR NON-RANDOMIZED
32
It may be either randomized or non-randomized?
EXPERIMENTAL STUDIES
33
It has several types including parallel design, crossover design, factorial design, randomized withdrawal approach, adaptive design, superiority design, and non-inferiority design.
CLINICAL TRIAL DESIGNS
34
Randomization type:
• SIMPLE RANDOMIZATION
• BLOCK RANDOMIZATION
• STRATIFIED RANDOMIZATION
• CO-VARIATE ADAPTIVE RANDOMIZATION/MINIMIZATION
• RANDOMIZATION BY BODY HALVES OR PAIRED ORGANS (SPLIT BODY TRIALS)
• CLUSTERED RANDOMIZATION
• ALLOCATED BY RANDOMIZED CONSENT (ZELEN TRUALS)
35
This is the most frequent design wherein each arm of the study group is allocated a particular treatment (placebo(an inert substance)/therapeutic drug)
PARALLEL - RANDOMIZED
36
The patient in this trial gets each drug and the patients serve as a control themselves.
CROSSOVER - RANDOMIZED
37
Two or more interventions on the participants and the study can provide information on the interactions between the drugs.
FACTORIAL - NON-RANDOMIZED
38
This study evaluates the time/duration of the drug therapy.
RANDOMIZED WITHDRAWAL APPRACH - RANDOMIZED
39
Recruit patients with the same characteristics.
MATCHED PAIRS - POST APPROVAL STUDY
40
It is the most frequently performed clinical research.
This type of research is undertaken to analyze the presence or absence of a disease/condition, potential risk factors, and prevalence and incidence rates in a defines population.
OBSERVATIONAL RESEARCH USING CROSS-SECTIONAL STUDY DESIGN
41
Clinical trials may be ___ or ___ depending on the type of intervention.
THERAPEUTIC or NON-THERAPEUTIC TYPE
42
The _____ of clinical trial uses a drug that mey be beneficial to the patient
THERAPEUTIC
43
A ____ clinical trial, the participant does not benefit from the drug. It provide additional knowledge of the drug for future improvements.
NON-THERAPEUTIC TYPE
44
It is the most significant document in a clinical study.
It contains the information collected by the investigator about each subject participating in a clinical study/trial.
CASE RECORD/REPORT FORM (CRF)
45
A clinical study is conducted by a?
SPONSOR or a CLINICAL RESEARCH ORGANIZATION (CRO)
46
Examines too low (1/100th) concentrations (micro-dosing) of the drug for less time. Study the pharmacokinetics and determine the dose for phase I studies.
SAFETY ASSESSMEMT
47
Around <50 healthy subjects are recruiter. Establishes a safe dose range, and the MTD. Examines the pharmacokinetic and pharmacodynamic effects.
PHASE I
48
Recruiting around 5-100 patients of either sex. Examines the effective dosage and the therapeutic effects on patients. It decides the therapeutic regimen and drug-drug interactions.
PHASE II
49
More than 300 patients (up to 3000) of either sec are recruited in this study and ate multicentric trials. Premarketing phase examined the efficacy and the safety of the drug. Comparison of the test drug with the placebo/standard drug. Adverse drug reaction/adverse events are noted. Initiate the process of NDA with appropriate regulatory agencies like FDA.
PHASE III
50
After approval/post-licensure and post-marketing studies/surveillance studies. Following up on the patients for an exceptionally long time for potential adverse reactions and drug-drug interactions.
PHADE IV
51
MTD
MAXIMUM TOLERATED DOSE
52
SAD
SINGLE ASCENDING DOSE
53
MAD
MULTIPLE ASCENDING DOSE
54
NDA
NEW DRUG APPLICATION
55
FDA
FOOD AND DRUGS ADMINISTRATION
56
Phase I clinical trials:
• DOSE ESCALATION
• SAFETY MONITORING
• MAXIMUM TOLERABLE DOSE
57
Phase I trials typically start with a very low dose of the investigational product and gradually increase the dose in a controlled manner.
DOSE ESCALATION
58
Participants are closely monitored for any adverse events or side effects, and the dose is adjusted accordingly.
SAFETY MONITORING
59
The trial aims to identify the maximum tolerated dose (MTD), which is the highest dose that can be safely administered without causing unacceptable side effects:
MAXIMUN TOLERATED DOSE
60
Phase II Clinical Trials:
• EFFICACY EVALUATION
• SAFETY PROFILE
• DOSE OPTIMIZATION
61
Determine if the drug shows promising results in treating the target condition.
EFFICACY EVALUATION
62
Monitor and assess potential side effects and risks associated with the treatment.
SAFETY PROFILE
63
Identify the optimal dosage that balances effectiveness and safety for patients.
DOSE OPTIMIZATION
64
Study Design and Methodology:
• PROTOCOL DEVELOPMENT
• RANDOMIZATION
• BLINDING
65
Study Design and Methodology:
• PROTOCOL DEVELOPMENT
• RANDOMIZATION
• BLINDING
66
Create a detailed plan outlining study procedures, endpoints, and statistical methods.
PROTOCOL DEVELOPMENT
67
Assign participants to treatment groups to minimize bias and ensure statistical validity.
RANDOMIZATION
68
implement single ir double-blinding to prevent bias in data collection and analysis.
BLINDING
69
Patient Population and Recruitment:
• INCLUSION CRITERIA
• EXCLUSION CRITERIA
• RECRUITMENT STRATEGIES
70
Specific disease characteristics, age range, and health status for eligibility.
INCLUSION CRITERIA
71
Conditions or factors that could interfere with the study or patient safety.
EXCLUSION CRITERIA
72
Outreach through healthcare providers, patient advocacy groups, and targeted advertising.
RECRUITMENT STRATEGIES
73
Outreach through healthcare providers, patient advocacy groups, and targeted advertising.
RECRUITMENT STRATEGIES
74
Efficacy Endpoints and Assessments
• PRIMARY ENDPOINT
• SECONDARY ENDPOINT
• BIOMARKERS
• QUALITY OF LIFE
75
Main outcome measure, such as tumor size reduction ot symptom improvement.
PRIMARY ENDPOINT
76
Additional measures to support primary endpoint and gather more data.
SECONDARY ENDPOINT
77
Biological indicators used to track treatment response and disease progression.
BIOMARKERS
78
Patient-reported outcomes to assess overall well-being and treatment impact.
QUALITY OF LIFE
79
Safety Monitoring and Data Collection
• ADVERSE EVENT REPORTING
• VITAL SIGNS MONITORING
• LABORATORY TESTS
80
Systematic documentation of any unexpected medical occurrence during the trial.
ADVERSE EVENT REPORTING
81
Regular checks of blood pressure, heart rate, and other essential health indicators.
VITAL SIGNS MONITORING
82
Phase III Clinical Trials:
• LARGE-SCALE TESTING
• COMPARATIVE STUDIES
• LONG-TERM EFFECTS
• REGULATORY SUBMISSION
83
Phase III Trial Design and Enrollment
• PROTOCOL DEVELOPMENT
• PATIENT RECRUITMENT
• RANDOMIZATION
• TREATMENT ADMINISTRATION
84
Involves hundreds to thousands of patients across multiple centers.
LARGE-SCALE TESTING
85
Often compares new treatment to current standard of care ot placebo.
COMPARATIVE STUDIES
86
Monitors for side effects and evaluates long-term efficacy.
LONG-TERM EFFECTS
87
Data from Phase III trials ate crucial for regulatory approval.
REGULATORY SUBMISSION
88
Detailed plan outlining trial objectives, design, and methods.
PROTOCOL DEVELOPMENT
89
Rigorous screening process to ensure eligible participants.
PATIENT RECRUITMENT
90
Patients randomly assigned to treatment ot control groups.
RANDOMIZATION
91
Strict adherence to protocol for dosing and follow-up.
TREATMNET ADMINISTRATION
92
Regulatory Approval Process for Phase III:
• PRE-NDA MEETING
• NDA SUBMISSION
• FDA REVIEW
• ADVISORY COMMITTEE
93
Discussion with regulatory agency about submission requirements.
PRE-NDA MEETING
94
Comprehensive application including all clinical and non-clinical data.
NDA SUBMISSION
95
Thorough evaluation of submitted data by expert panels.
FDA REVIEW
96
Public meeting to discuss benefits and risks of the new treatment.
ADVISORY COMMITTEE
97
Among the most significant aspects of a clinical trial?
AUDIT
98
A systematic process of evaluating the clinical trial operations at the site.
AUDIT
99
It ensures that the clinical trial process is conducted according yo the protocol, and predefined quality system procedures, following GCP guidelines, and according to the requirements of regulatory authorities.
AUDIT
100
The NDA Submission and Review Timeline
• NDA SUBMISSION
• FDA REVIEW
• FDA APPROVAL
101
The completed NDA us filed with the FDA review.
NDA SUBMISSION
102
The FDA has 10 months to review the NDA and make a decision.
FDA REVIEW
103
If approved, the drug can be marketed and sold in the United States.
FDA APPROVAL
104
Phase IV Clinical Trials:
• SAFETY MONITORING
• EFFICACY STUDIES
• POPULATION IMPACT
• COST-EFFECTIVESS
105
Continuous tracking of adverse events in real-world settings.
SAFETY MONITORING
106
Additional research to confirm long-term benefits and risks.
EFFICACY STUDIES
107
Assessing treatment effects in diverse patient groups.
POPULATION IMPACT
108
Evaluating economic impacts of the nee treatment.
COST-EFFECTIVENESS
109
Key differences Between IND and NDA
• FOCUS
• TIMING
• PREVIEW PROCESS
110
Safety and feasibility of new drug candidate.
IND
111
Comprehensive evaluation of efficacy ad safety.
NDA
112
Preclinical to early clinical trials.
IND
113
Late-stage clinical trials and manufacturing data.
NDA
114
30-day FDA review
IND
115
10-month comprehensive FDW review
NDA
116
Strategies tor Successful NDA submission:
• EFFECTIVE COMMUNICATION
• ROBUST DATA
• METICULOUS PLANNING
• REGULATORY COMPLIANCE
117
Maintain open dialogue with the FRW throughout the NDA process.
EFFECTIVE COMMUNICATION
118
Ensure comprehensive and well-organized clinical trial data in the NDA.
ROBUST DATW
119
Develop a detailed timeline and strategy for NDW preparation and submission.
METICULOUS PLANNING
120
Adhere to strictly to all FRW guidelines and regulations throughout the process.
REGULATORY COMPLIANCE
121
identifical in appearance to the treatment drug.
PLACEBO
